Lotte Biologics Wins First Major Commercial Production Deal for Songdo Plant 1
Lotte Biologics has secured its first major commercial production contract for Plant 1 at its Songdo Bio Campus in Incheon, positioning itself as a key player in the global contract development and manufacturing organization (CDMO) market. The company has signed a contract with a global pharmaceutical company for the production of key products, including active pharmaceutical ingredients (APIs) and finished drug products, with full-scale operations targeted for 2027.
The undisclosed contract value and specific terms indicate the significance of this deal, as it provides a basis for the company to ramp up utilization as the facility begins operations.
Brief written by urgent.news from BusinessKorea's own syndicated text. Machine-written — may contain errors; check the original before relying on it.